New drugs for heart failure

November 24, 2019

Heart failure and reduced ejection fraction (HFrEF) now has two new drugs

  1.    Sacubitril/Valsartan
  2.    Sodium-glucose cotransporter 2 (SGLT2) inhibitors

healthy soch

New Delhi, November 24, 2019:

In the DAPA-HF trial, treatment with the SGLT2 inhibitor dapagliflozin on top of standard HFrEF medicines, compared with standard medicines only, led to significantly improved risk not only for its clinical composite primary endpoint, but for mortality and a slew of other meaningful secondary outcomes.

The benefits are not mediated by the well-recognized antiglycemic effects of the SGLT2 inhibitor.

DAPA-HF entered more than 4700 patients with HFrEF without regard to their diabetes status.

www.healthysoch.com

Patients assigned to receive dapagliflozin on top of standard HFrEF medicines showed at least a one-fourth drop in risk of the clinical primary endpoint compared with those on standard medicines alone over a median of 18 months — also regardless of diabetes status.

The drug had also been shown, in the recent DEFINE-HF trial, to improve symptoms and quality of life in a similar HF population, again in patients with or without diabetes.

SGLT2 inhibitor benefits for HF endpoints in patients who primarily have diabetes have already been established.

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Safe disposal of expired and unused medicines

healthyoch New Delhi, May 09, 2019 : It is the
Healthcard for Cancer Treatment

Healthcard for Cancer Treatment

New Delhi, August 02, 2017: Rashtriya Swasthya Bima Yojana (RSBY), a